

1

2 **Title:**

3 “Efficacy and Safety of Fixed Combination of Hydroxychloroquine with Azithromycin  
4 Versus Hydroxychloroquine and Placebo in Patients with Mild COVID-19:  
5 Randomized, double blind, Placebo controlled trial”

6 **Authors**

7 Ivonne A Roy-García<sup>1¶</sup>, Moises Moreno-Noguez<sup>2¶</sup>, Rodolfo Rivas-Ruiz<sup>1\*</sup>, Marta  
8 Zapata-Tarres<sup>3&</sup>, Marcela Perez-Rodriguez<sup>1&</sup>, Magaly A Ortiz-Zamora<sup>4</sup>, Lourdes  
9 Gabriela Navarro-Susano<sup>4</sup>, Lilia M Guzman-Rivas<sup>5</sup>, Luis Rey Garcia-Cortes<sup>6</sup>, Icela  
10 Palma-Lara<sup>7</sup>, Pedro Gutierrez-Catrellón<sup>3,8, #a, #b.</sup>

11

12 1. Centro de Adiestramiento en Investigación Clínica, División de Investigación  
13 Clínica, Instituto Mexicano del Seguro Social, México.

14 2. Unidad de Medicina Familiar #55 Zumpango, Órgano de Operación  
15 Administrativa Desconcentrada Estado de México Oriente, Instituto Mexicano  
16 del Seguro Social, México.

17 3. Fundación IMSS, A.C, México

18 4. Unidad de Medicina Familiar #28, Instituto Mexicano del Seguro Social,  
19 México.

20 5. Unidad de Medicina Familiar #52 Cuautitlán Izcalli, Órgano de Operación  
21 Administrativa Desconcentrada Estado de México Oriente, Instituto Mexicano  
22 del Seguro Social, México.

1

23 6. Coordinación Auxiliar Médica de Investigación en Salud, Órgano de  
24 Operación Administrativa Desconcentrada Regional Estado de México  
25 Oriente, Instituto Mexicano del Seguro Social, México.

26 7. Centro de Investigación Translacional en Ciencias de la Salud, México

27 #a Hospital Dr. Manuel Gea González, México

28

29 \* Corresponding author

30 Email:rivasrodolfo@gmail.com (RR)

31

32

## 33 **Abstract**

34

35 To determine the efficacy and safety of fixed combination of  
36 hydroxychloroquine/azithromycin (HCQ+AZT) compared to hydroxychloroquine  
37 (HCQ) alone or placebo in mild COVID-19 outpatients to avoid hospitalization.

## 38 **Materials and methods**

39 This randomized, parallel, double-blind clinical trial included male and female  
40 patients aged 18 and 76 years non COVID vaccinated, who were diagnosed with  
41 mild COVID-19 infection. All patients underwent liver and kidney profile test, as well  
42 as a health questionnaire and clinical revision to document that they did not have  
43 uncontrolled comorbidities. They were randomly assigned to one of the three  
44 treatment arms: 1) hydroxychloroquine with azithromycin 200 mg/250 mg every 12  
45 hours for five days followed by hydroxychloroquine 200 mg every 12 hours for 5  
46 days; 2) hydroxychloroquine 200 mg every 12 hours for ten days; or 3) placebo every  
47 12 hours for ten days. The primary outcome of the study was hospitalization, while  
48 the secondary outcomes were disease progression, pneumonia, use of  
49 supplemental oxygen, and adverse events. This study was registered in  
50 [clinicaltrials.gov](https://clinicaltrials.gov) with the NCT number of 04964583.

## 51 **Results**

52 A total of 92 participants were randomized. Of whom, 30 received HCQ+AZT, 31  
53 received HCQ, and 31 received placebo. The median age was 37 years, 27.2% of  
54 the participants had comorbidities, and the global incidence of hospitalization was

55 2.2%. The incidence of hospitalization was 6.7% (2/30) in the HCQ+AZT group  
56 compared to the HCQ or placebo groups, in which there were no hospitalizations.  
57 Progression of disease was higher in the HCQ group [RR=3.25 (95% CI, 1.19-8.87)]  
58 compared with placebo group. There was no statistical difference between the  
59 HCQ+AZT group and the placebo group in progression of disease. The incidence of  
60 pneumonia was 30% in the HCQ+AZT group, 32.2% in the HCQ group, and 9.6% in  
61 the placebo group (HCQ + AZT vs Placebo; p=0.06). There was a significant risk of  
62 pneumonia versus placebo only in the HCQ group [RR=3.33 (95% CI, 1.01-10.9)].  
63 Supplemental oxygen was required by 20% (6/30) of the patients in the HCQ+AZT  
64 group, 6.4 (2/31) of the patients in the HCQ group, and 3.2% (1/31) of the patients  
65 in the placebo group, [(HCQ + AZT vs Placebo; p=0.100), (HCQ vs Placebo,  
66 p=0.610)]. There was no statistical difference between groups for negative test  
67 (PCR) on day 11. The most frequent adverse events were gastrointestinal  
68 symptoms. No lengthening of the QT interval was observed in patients receiving  
69 HCQ+AZT or HCQ.

## 70 **Conclusion**

71 The use of HCQ+AZT does not decrease the risk of hospitalization in patients with  
72 mild COVID-19. The use of HCQ increases the risk of progression and pneumonia.

73

74

## 75 Introduction

76 At the end of December 2019, a new viral infection belonging to the Coronavirus  
77 family emerged in China [1], which spread rapidly worldwide [2] and was declared a  
78 pandemic by the WHO in March 2020. The COVID-19 disease requires  
79 hospitalization in 20% of patients, 33.7% of whom require admission to the intensive  
80 care unit, with a mortality rate reaching up to 62.4% [3]. The need to find an urgent  
81 treatment to reduce the impact of the pandemic has led to the use of different  
82 therapeutic options, among them is the fixed combination of hydroxychloroquine and  
83 azithromycin which became a promising option [4,5].

84 Hydroxychloroquine has antiviral activity, inhibits endosome acidification, interferes  
85 with virus fusion to the cell, exhibits non-specific antiviral activity in vitro against a  
86 wide range of emerging viruses (HIV, dengue, hepatitis C, SARS, and MERS), and  
87 more recently against SARS CoV-2 in addition to its anti-inflammatory activity [6,7].  
88 On the other hand, azithromycin is a macrolide antibiotic indicated for airway  
89 infections, which has shown anti-inflammatory and antiviral effects in vitro [8], which  
90 is why it was proposed as an accessible and cost-effective option for SARS CoV-2  
91 infection [9].

92 Even if these drugs have demonstrated efficacy in vitro nowadays, clinical results on  
93 the beneficial effect of the fixed combination HCQ+AZT in hospitalized or  
94 mechanically ventilated patients are inconsistent [10,11], which is attributed to the  
95 delayed initiation of treatment when viral replication and inflammatory response  
96 characterized by an increased cytokine storm have already occurred [12]. Therefore,  
97 it is hypothesized that early use of these drugs is necessary to achieve benefits to

98 prevent hospitalizations. This study aimed at determining the efficacy and safety of  
99 the fixed combination of HCQ+AZT compared to HCQ or placebo in mild COVID-19  
100 outpatients to avoid hospitalizations [13].

## 101 [Methods](#)

### 102 [Trial design](#)

103 This study was designed as a multicenter, parallel, double-blind, randomized clinical  
104 trial. The study was conducted in two public ambulatory family medicine units, in  
105 Mexico City (UMF No. 28) and at the State of México (UMF No. 52) both of the  
106 Instituto Mexicano del Seguro Social (IMSS), which is the national social security  
107 institute. The trial was designed and conducted by the authors. The protocol was  
108 approved by the National Research Committee institution's review board of the  
109 IMSS with the number R-2020-785-138 and by COFEPRIS, the Mexican drug  
110 regulatory agency. Written informed consent was obtained from each of the included  
111 participants. Ultra laboratories were the sponsor of the study; nonetheless, they were  
112 not involved in protocol or the analysis of results or in the preparation of the  
113 manuscript.

114 The trial was registered in [clinicaltrials.gov](https://clinicaltrials.gov) (Clinical Trials: NCT04964583). This  
115 report follows the CONSORT guidelines.

### 116 [Eligible subjects](#)

117 The study included patients aged 18-76 years who were diagnosed with mild COVID-  
118 19 with acute respiratory disease and who met the current operational definition of  
119 the Ministry of Health of Mexico, which included the presence of a major symptom  
120 such as headache, fever, cough, dyspnea, and any of the following minor symptoms:  
121 myalgia, arthralgia,odynophagia, chills, chest pain, rhinorrhea, anosmia, dysgeusia,

122 or conjunctivitis [14]. The diagnosis was confirmed by RT-PCR for SARS-CoV-2, the  
123 severity of the disease was evaluated with the NEWS scale, patients with a score  $\leq 4$   
124 points were considered to have mild disease. Patients with cardiac disorders with  
125 delayed cardiac conduction (QT segment  $\geq 450$  ms), pregnant or lactating women,  
126 patients with hypersensitivity to study drugs, patients with chronic renal failure with  
127 (eGFR $<40$  mL/min), patients with a history of retinopathy or macular degeneration,  
128 known Glucose 6 Phosphate Dehydrogenase (G6PD) deficiency, patients with liver  
129 disease, cirrhosis or those using the following medications: colchicine, ergotamine,  
130 dihydroergotamine, citalopram, hydroxyzine, domperidone, piperazine,  
131 antiarrhythmic drugs class IA and III and antidepressant medications were excluded  
132 from the study.

### 133 Intervention

134 Participants were randomly assigned to one of the three treatment arms. The  
135 participants in Group 1 (HCQ+AZT) received hydroxychloroquine 200  
136 mg/azithromycin 250 mg orally every 12 hours for 5 days, followed by  
137 hydroxychloroquine 200 mg every 12 hours for 5 more days. The participants in  
138 Group 2 (HCQ) received only hydroxychloroquine 200 mg orally every 12 hours for  
139 10 days. The participants in Group 3 received an oral placebo every 12 hours for 10  
140 days. All three treatment groups received symptomatic treatment for the  
141 management of COVID-19, the current standard was at discretion of the treating  
142 physician based on acetaminophen, non-steroidal analgesics, antihistamines and  
143 Ivermectin. A computerized random number sequence was generated for  
144 assignment to study treatment groups and was stratified according to center.  
145 Randomization was carried out by one of the investigators who did not participate in

146 the inclusion of patients or in the delivery of medication. The medical staff was  
147 responsible for the recruitment and selection of participants and the evaluation of the  
148 correct allocation of treatment according to the randomization. Adherence to  
149 treatment was evaluated by counting the tablets during the medical consultation and  
150 by the intake recorded by the participants in the digital application for smartphones.

### 151 Follow-up

152 The follow-up was carried out through a Web App on a smartphone explicitly  
153 elaborated for the research project (digital monitoring), for which the participant was  
154 previously instructed, recording the medication intake, adverse events, oxygen  
155 saturation, and temperature during the ten days of the treatment. A clinical  
156 examination was performed at the time of inclusion, on days 6 and 11 after initiating  
157 the treatment, in which an evaluation of the severity of the disease was carried out  
158 along with an RT-PCR test, electrocardiogram and follow-up laboratory studies,  
159 count of tablets to evaluate therapeutic adherence, and radiography taken at the  
160 beginning of the study and on day 11. On day 21 of the follow-up, the participants  
161 were called by phone to evaluate symptoms and to investigate whether the patient  
162 had returned to routine activities, required hospitalization, or had any of the  
163 secondary outcomes. All participants who showed a change suggestive of  
164 deterioration (oxygen saturation less than 90% in room air, and shortness of breath  
165 or pneumonia) during their digital follow-ups were contacted by a specialized  
166 physician to confirm the data and establish the behavior to follow.

167



## 168 Outcomes

169 The primary outcome of the study was hospitalization during the 21 days of the  
170 follow-up. The secondary outcomes included disease progression, which was  
171 defined by oxygen saturation less than 90%, dyspnea, or pneumonia [15], use of  
172 supplemental oxygen, the presence of adverse events during the 21 days of follow-  
173 up, and PCR results on days 6 and 11 of the follow-up.

## 174 Drug Safety

175 All adverse events reported by the participants during the study period in the  
176 electronic patient diary app or during medical consultations were recorded. To  
177 assess the safety of the drug, QT intervals were measured by a certified cardiologist  
178 using the Bazett formula by performing a 12-lead electrocardiogram at the inclusion  
179 visit, on days 6 and 11 of the follow-up.

## 180 Sample Size

181 The sample size was calculated using a comparative study formula. An expected  
182 difference of 40% in the clinical response between HCQ+AZT treatment and placebo  
183 was considered, with a margin of superiority of 10%, an  $\alpha$  error of 5%, and a  
184 statistical power of 80%. The estimated sample size obtained from the calculation  
185 was 84 participants, 28 participants per group, to which 20% was added for possible  
186 losses, obtaining a sample size of 105 participants. Due to the decrease in the  
187 number of COVID-19 patients, only 92 participants were included.

## 188 Statistical Analysis

### 189 Therapeutic Efficacy Analysis:

190 The therapeutic efficacy was assessed using an intention-to-treat analysis. The  
191 variables considered for the determination of efficacy were as follows:  
192 hospitalization, disease progression, pneumonia, and use of supplemental oxygen.

193 Clinical Safety Analysis:

194 The safety analysis was carried out considering all the participants regardless of  
195 their completion of the study. The frequency and severity of the adverse events  
196 presented by the participants during the study were determined, and a comparison  
197 was made according to the types of treatment given using the Pearson's  $X^2$  test or  
198 Fischer exact test.

199 Descriptive and Inferential Statistics

200 A descriptive analysis was carried out to determine the general characteristics of the  
201 population [16].

202 To determine if there were differences in the baseline status of the population by the  
203 treatment assignment, the ANOVA test was used for systolic and diastolic pressure,  
204 PCR (CT), total leukocytes and lymphocytes, the Kruskal-Wallis test was used for  
205 age, BMI, temperature, oxygen saturation, NEWS Score, Glucose, urea, lactic  
206 dehydrogenase, GGT, transaminases, serum iron, neutrophils and platelets, and the  
207 Pearson's  $X^2$  test or Fisher's exact test was used for sex, comorbidities, smoking  
208 and Ivermectin.

209 The incidence of hospitalization, disease progression, pneumonia, use of  
210 supplemental oxygen and negative test (PCR) on day 11 was determined according  
211 to the treatment assignment as a measure of association. The relative risk (RR) was  
212 calculated, with its 95% confidence interval, and the number needed to treat (NNT)  
213 and number needed to harm (NNH) were calculated as a measure of potential impact  
214 [17].

215 Alpha was set at 5%, all data were analyzed by using IBM SPSS v.28 (IBM Corp,  
216 NY, USA).

## 217 Results

### 218 Study population

219 Figure 1 shows the number of participants included in the study and assigned to  
220 treatments. A total of 92 participants were randomized between January and June  
221 2021 and included in the intention-to-treat analysis. In the per-protocol analysis, 6  
222 participants were excluded, four patients for withdrawing informed consent in the  
223 HCQ+AZT group and one for medication error, and one participant for withdrawing  
224 informed consent in the HCQ group. None of the patients was excluded in the  
225 placebo group.

226 The general characteristics of the population are shown in Table 1. The median age  
227 was 37 years, 27.2% of the patients had comorbidities, the median BMI was 26.9.  
228 The analysis of the time of evolution at the initiation of treatment revealed a median  
229 of 5 days, with a median saturation of 94%. The incidence of hospitalization in the  
230 study population was 2.2%. The analysis of the laboratory studies revealed that  
231 27.2% of the participants had elevated lactic dehydrogenase levels, 45.7% had  
232 elevated gamma-glutamyl transferase levels, 48.9% had elevated levels of some  
233 type of transaminase, 8.7% had neutropenia, and 21.7% had thrombocytopenia at  
234 the beginning of the study.

235 The analysis of the symptoms at the beginning of the study showed that 81.5% of  
236 the participants had a cough, 77.2% had a headache, 62% had fatigue, 32.6% had  
237 a fever, 23.9% had arthralgia, 8.7% had dyspnea, 23.9% had a sore throat, 32.6%  
238 had anosmia, and 30.4% had dysgeusia.

239 Table 2 shows the baseline characteristics of the population according to the  
240 allocation to the treatment arm. There were no significant differences for any of the  
241 variables analyzed.

### 242 Primary Outcome

243 The analysis of the therapeutic efficacy to reduce the risk of hospitalization revealed  
244 that the incidence of the outcome in the HCQ+AZT group was 6.7% (2/30) compared  
245 to the HCQ group and the placebo group, in which there were no hospitalizations  
246 (Table 3).

### 247 Secondary Outcomes

248 The incidence of disease progression was 30% (9/30) in the HCQ+AZT group,  
249 41.9% (13/31) in the HCQ group, and 12.9% (4/31) in the placebo group. The RR  
250 for the HCQ+AZT group versus placebo was 2.32 (95% CI, 0.80-6.74; p=0.10) and  
251 the RR for the HCQ group versus placebo was 3.25 (95% CI, 1.19-8.87; p=0.01).  
252 Even though there was a statistically significant risk for developing pneumonia in the  
253 HCQ group compared to the placebo group [RR=3.33 (CI 95% 1.10, 10.9; p=0.02)],  
254 the pneumonia incidence was 30% (9/30) in the HCQ+AZT group, 32.2% (10/31) in  
255 the HCQ group and 9.6% (3/31) in the placebo group. The fixed combination of  
256 HCQ+AZT did not benefit compared to placebo. The frequency of patients who  
257 required supplemental oxygen was 20% (6/30) in the HCQ+ AZT group, 6.4% (2/31)  
258 in the HCQ group, and 3.2 % (1/31) in the placebo group. There were no significant  
259 differences between the groups. (Figure 1) There was no statistical difference  
260 between groups for negative test (PCR) on day 11.

261 Table 4 shows the efficacy of a placebo for secondary outcomes. For the group  
262 receiving placebo, we found disease progression in 12.9% (4/31) of participants

263 compared to the group receiving active drugs (HCQ+AZT, HCQ) in 36.1% (22/61),  
264 [RR of 0.35 (0.13, 0.94; p=0.02)]. When analyzing pneumonia development, the  
265 results showed an incidence of 9.6% (3/31) compared to an incidence of 31% (19/61)  
266 in the group with HCQ+AZT, HCQ, [RR of 0.31 (0.09, 0.96, p=0.02)]. We could not  
267 observe differences in the use of supplemental oxygen.

## 268 Adverse Events

269 The most frequent adverse events were gastrointestinal symptoms with a rate of  
270 16.6% (nausea, vomiting, heartburn, abdominal pain and distension), bradycardia  
271 with a rate of 6.4%, platelet elevation with a rate of 4.3%, and hypertriglyceridemia  
272 with a rate of 3.8%. Adverse events occurred with similar frequency between the  
273 different treatment groups. The analysis of whether there were differences in the  
274 QTc interval by the treatment group showed no differences in those who received  
275 HCQ+AZT or HCQ compared to the placebo group (Table 5).

## 276 Discussion

277 At the beginning of the pandemic, the fixed combination of HCQ +AZT was proposed  
278 as a possible therapeutic option based on its antiviral and anti-inflammatory activity  
279 in vitro. However, clinical studies yielded inconsistent results. Therefore, this  
280 research project is conducted [18].

281 The study population consisted of participants with mild COVID-19, who had a low  
282 risk of complications. Of whom, only 2% required hospitalization. These data  
283 coincide with those reported in a population study from Alberta, Canada [19].

284 The results of this study suggest that the fixed combination of HCQ+AZT for the  
285 treatment of patients with mild COVID-19 does not reduce the risk of hospitalization

286 compared to the use of HCQ alone or placebo. These results coincide with those  
287 reported in a Brazilian clinical trial on patients with mild and moderate COVID-19,  
288 which showed no significant differences for any of the treatment groups (HCQ+AZT,  
289 HCQ, or placebo) in terms of hospitalization or mechanical ventilation [20]. These  
290 results also coincide with those reported by other authors who evaluated the  
291 separate use of HCQ or AZT and found no benefit to reduce the risk of  
292 hospitalization, mechanical ventilation, or mortality [11,21–25].

293 The analysis of the secondary outcomes revealed that the administration of HCQ  
294 increased the risk of progression and pneumonia compared to placebo. However,  
295 for the combination of HCQ+AZT, the results showed only a trend in the risk for  
296 pneumonia, with no statistical significance, due to lack of statistical power. When we  
297 combined both active treatments against placebo for progression and pneumonia,  
298 we were able to show these differences.

299 The increase in the risk of damage after the use of the combination of HCQ+AZT,  
300 as in this study, was also reported by Kureder et al. who found a higher risk of  
301 mortality in patients who received this combination treatment, even in the  
302 multivariate model. However, these results were derived from an observational study  
303 where it was possible that the patients who received the use of HCQ+AZT had a  
304 more severe form of the disease at baseline, while in the present study, the  
305 participants included in the three treatment groups had mild symptoms [26].

306 Our results on the lack of benefit for the different outcomes of the study contrast  
307 with the results reported by Gautret et al., who highlighted the efficacy of the  
308 combination of HCQ+AZT for viral clearance on day six of treatment, in this study,  
309 no significant differences were found in the negativization of the PCR at day 11. It

310 is possible to attribute the differences to the design of the study, non-  
311 randomization, the evaluation of an intermediate regulator as an outcome, and not  
312 evaluating other clinically relevant outcomes such as mechanical ventilation or  
313 mortality [27].

314 Although an antiviral effect against SARS-CoV-2 was found for HCQ and AZT in  
315 vitro, the use of HCQ in this study conditioned a higher risk of progression and  
316 pneumonia. This paradoxical response suggests that the drug could impair the  
317 immune response, conditioning a delay in the cellular and adaptive immune  
318 response, as shown by Roques et al. analyzing the effect of chloroquine on  
319 Chikungunya virus infection, who highlighted the contrast between the in vitro  
320 antiviral effect of chloroquine and the exacerbation of the disease in vivo and who  
321 reported that they are like the results reported by Maisonnasse, as well as our  
322 results [28,29].

323 Another concern about the use of HCQ+AZT for the treatment of COVID-19  
324 infection is the risk of cardiovascular complications by prolonging the QT interval  
325 and causing polymorphic ventricular tachycardia in the form of Torsade de Pointes  
326 and death [30]. In this study, no differences in QT segment duration or fatal  
327 arrhythmias were documented in the three treatment groups, suggesting that  
328 significant cardiac involvement and arrhythmias in patients infected with COVID-19  
329 have a multifactorial etiology and are more common in patients with severe forms  
330 of the disease, comorbidities, and advanced age [31, 32]. The absence of  
331 cardiovascular complications in our population can be explained by the inclusion of  
332 a young population, with a low prevalence of comorbidities and mild disease.

333 The most frequent adverse events were mild and gastrointestinal symptoms,  
334 characterized by nausea, vomiting, pain, and abdominal distension.  
335 The sample size calculation was 105 participants. However, the study was stopped  
336 after the inclusion of 92 participants due to a decrease in the number of patients in  
337 Mexico prior to the third pandemic wave. Participants who received ivermectin as  
338 concomitant treatment were included. However, the use of Ivermectin wasn't  
339 associated with hospitalization, pneumonia and disease progression.

## 340 Conclusion

341 The use of HCQ+AZT did not show efficacy in reducing the risk of hospitalization in  
342 patients with mild COVID-19 with controlled comorbidities. The use of HCQ and  
343 HCQ+AZT was associated with an increased risk of disease progression. The  
344 adverse events observed were mild and infrequent, predominantly consisting of  
345 gastrointestinal symptoms, without presenting cardiac alterations. Digital  
346 monitoring is a very valuable tool for the early detection of infection progression  
347 data. It is important to emphasize that empirical treatments were administered  
348 during the initial phases of the pandemic. It is important to continue generating  
349 evidence on this disease based on randomized control trials.

## 350 Acknowledgments

351 This study is part of the doctoral studies at the Instituto Politécnico Nacional of the  
352 doctoral candidate Ivonne Anali Roy-Garcia.  
353 We would like to thank all the patients who participate in this study, nevertheless all  
354 the requirements of the protocol. We also like to thank the directors of the Organ of  
355 Decentralized Administrative Operation Regional State of Mexico East and the



356 directors of the Family Medicine Unit 52 Cuautitlán Izcalli and the Family Medicine  
357 Unit 28 for the facilities to carry out this research, Chief of Medical Benefit  
358 Services, Dr. María de los Ángeles Dichi Romero, Coordinator of Planning and  
359 Institutional Liaison, Dr. Olga Margarita Bertadillo Mendoza, Director of UMF 52,  
360 Dr. Irlanda León Bojorges and to the laboratory staff of the UMF 28 and the  
361 epidemiology, Dra. Brenda Jessica Espinosa Armenta.

## 362 [References](#)

- 363 1. Coronaviridae Study Group of the International Committee on Taxonomy of  
364 Viruses. The species Severe acute respiratory syndrome-related coronavirus:  
365 classifying 2019-nCoV and naming it SARS-CoV-2. *Nat Microbiol.* 2020  
366 Apr;5(4):536–44.
- 367 2. Huang M, Yang Y, Shang F, Zheng Y, Zhao W, Luo L, Han X, Lin A, Zhao H, Gu  
368 Q, Shi Y, Li J, Xu X, Liu K, Deng Y, Cao Q WW. Clinical Characteristics and  
369 Predictors of Disease Progression in Severe Patients with COVID-19 Infection in  
370 Jiangsu Province, China: A Descriptive Study. *Am J Med Sci.* 2020;360(2):120–68.
- 371 3. Álvarez-Maldonado P, Hernández-Ríos G, Ambríz-Mondragón JC, Gordillo-  
372 Mena JA, Morales-Serrano DF, Reding-Bernal A, et al. Characteristics and  
373 mortality of Mexican patients with COVID-19 and mechanical ventilation. *Gac Med*  
374 *Mex.* 2021;157(1):97–101.
- 375 4. Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L, et al. A pilot study of  
376 hydroxychloroquine in treatment of patients with moderate COVID-19. *Zhejiang Da*  
377 *Xue Xue Bao Yi Xue Ban.* 2020 May 25;49(2):215–9.

- 378 5. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Sevestre J, Mailhe M,  
379 Doudier B, Aubry C, Amrane S, Seng P, Hocquart M, Eldin C, Finance J, Vieira  
380 VE, Tissot-Dupont HT, Honoré S, Stein A, Million M, Colson P, La Scola B, Veit V,  
381 Jacquier A, Deharo JC, RD. Clinical and microbiological effect of a combination of  
382 hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-  
383 day follow up: A pilot observational study. *Travel Med Infect Dis.* 2020;34:101663.
- 384 6. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and  
385 chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV)  
386 in vitro. *Cell Res.* 2020 Mar;30(3):269–71.
- 387 7. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine  
388 on viral infections: an old drug against today's diseases? *Lancet Infect Dis.* 2003  
389 Nov;3(11):722–7.
- 390 8. Andreani J, le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, Wurtz N, et  
391 al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-  
392 CoV-2 shows synergistic effect. *Microb Pathog.* 2020 Aug;145(104228).
- 393 9. Echeverría-Esnal D, Martín-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio  
394 Cuscó M, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of  
395 COVID-19: a review. *Expert Rev Anti Infect Ther.* 2021 Feb 19;19(2):147–63.
- 396 10. Kelly M, O'Connor R, Townsend L, Coghlan M, Relihan E, Moriarty M, et al.  
397 Clinical outcomes and adverse events in patients hospitalised with COVID-19,  
398 treated with off-label hydroxychloroquine and azithromycin. *Br J Clin Pharmacol.*  
399 2021 Mar;87(3):1150–4.

- 400 11. Albani F, Fusina F, Giovannini A, Ferretti P, Granato A, Prezioso C, et al.  
401 Impact of Azithromycin and/or Hydroxychloroquine on Hospital Mortality in COVID-  
402 19. *J Clin Med*. 2020 Aug 30;9(9):2800.
- 403 12. Gautret P, Million M, Jarrot PA, Camoin-Jau L, Colson P, Fenollar F, Leone M,  
404 La Scola B, Devaux C, Gaubert JY, Mege JL, Vitte J, Melenotte C, Rolain JM,  
405 Parola P, Lagier JC, Brouqui P RD. Natural history of COVID-19 and therapeutic  
406 options. *Expert Rev Clin Immunol*. 2020;16(12):1159–84.
- 407 13. Kim EJ, Coppa K, Hirsch JS, Abrahams S, Johnson J, Lesser M, et al.  
408 Examination of patient characteristics and hydroxychloroquine use based on the  
409 US Food and Drug Administration’s recommendation: a cross-sectional analysis in  
410 New York. . *BMJ Open*. 2021;11(2):e042965.
- 411 14. Secretaria de Salud de México. Lineamiento estandarizado para la vigilancia  
412 epidemiológica y por laboratorio de COVID-19” aprobado por el Comité Nacional  
413 para la Vigilancia Epidemiológica (CONAVE). 2020.
- 414 15. Morgenstern-Kaplan D, Buitano-Tang B, Martínez-Gil M, Zaldívar-Pérez Pavón  
415 A, Talavera JO. U-shaped-aggressiveness of SARS-CoV-2: Period between initial  
416 symptoms and clinical progression to COVID-19 suspicion. A population-based  
417 cohort study. *PLoS One*. 2020 Dec 3;15(12):e0243268.
- 418 16. Talavera JO, Rivas-Ruiz R. Clinical research IV. Relevancy of the statistical  
419 test chosen. *Rev Med Inst Mex Seguro Soc*. 2011;49(4):401–5.
- 420 17. Rivas-Ruiz R, Roy-García I, Pérez-Rodríguez M, Berea R, Moreno-Palacios J,  
421 Moreno-Noguez M, et al. The relevance and irrelevance of charts in clinical  
422 research. *Rev Alerg Mex*. 2020 Dec;67(4):381–96.

- 423 18. Andreani J, le Bideau M, Dufлот I, Jardot P, Rolland C, Boxberger M, et al. In  
424 vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2  
425 shows synergistic effect. *Microb Pathog.* 2020 Aug;145:104228.
- 426 19. Schwartz I, Boesen ME, Cerchiarо G, Doram C, Edwards BD, Ganesh A, et al.  
427 Assessing the efficacy and safety of hydroxychloroquine as outpatient treatment of  
428 COVID-19: a randomized controlled trial. 2021 Jun 18;9(2):E693-E702. . *CMAJ*  
429 *Open.* 2021 Jun 18;9(2):693–702.
- 430 20. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et  
431 al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.  
432 *N Engl J Med.* 2020 Nov 19;383(21):2041–52.
- 433 21. Skipper CP, KENBAAMLSW da. Hydroxychloroquine in Nonhospitalized  
434 Adults With Early COVID-19 : A Randomized Trial. *Ann Intern Med.* 2020  
435 Oct;173(8):623–31.
- 436 22. RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital  
437 with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.  
438 *Lancet.* 2021 Feb 13;397(10274):605–12.
- 439 23. PRINCIPLE Trial Collaborative Group. Azithromycin for community treatment of  
440 suspected COVID-19 in people at increased risk of an adverse clinical course in  
441 the UK (PRINCIPLE): a randomized, controlled, open-label, adaptive platform trial.  
442 *Lancet.* 2021 Mar 20;397(10279):1063–74.
- 443 24. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational  
444 Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. *N Engl J Med*  
445 2020 Jun 18;382(25):2411-2418. 2020 Jun 18;382(25):2411–8.

- 446 25. Reis G, Moreira Silva EADS, Medeiros Silva DC, Thabane L, Singh G, Park  
447 JJH, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and  
448 Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The  
449 TOGETHER Randomized Clinical Trial. . JAMA Netw Open. 2021 Apr  
450 1;4(4):e216468.
- 451 26. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al.  
452 Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.  
453 Lancet. 2020 Jun 20;395(10241):1907–18.
- 454 27. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.  
455 Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an  
456 open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020  
457 Jul;56(1):105949.
- 458 27. Roques P, Thiberville SD, Dupuis-Maguiraga L, Lum FM, Labadie K, Martinon  
459 F, et al. Paradoxical Effect of Chloroquine Treatment in Enhancing Chikungunya  
460 Virus Infection. Viruses. 2018 May 17;10(5):268.
- 461 28. Maisonnasse P, Guedj J, Contreras V, Behillil S, Solas C, Marlin R, et al.  
462 Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates.  
463 Nature 2020. 2020 Sep;585(7826):584–7.
- 464 29. Manolis AS, Manolis AA, Manolis TA, Apostolopoulos EJ, Papatheou D, Melita  
465 H. COVID-19 infection and cardiac arrhythmias. Trends Cardiovasc Med 2020  
466 Nov;30(8):451-460 . 2020;30(8):451–60.
- 467 30. Ramadan MS, Bertolino L, Zampino R, Durante-Mangoni E, Monaldi Hospital  
468 Cardiovascular Infection Study Group. Cardiac sequelae after coronavirus disease  
469 2019 recovery: a systematic review. Clin Microbiol Infect. 2021 Sep;27(9):1250–61.

470 31. Garcia-Zamora S, Lee S, Haseeb S, Bazoukis G, Tse G, Alvarez-Garcia J, et  
471 al. Arrhythmias and electrocardiographic findings in Coronavirus disease 2019: A  
472 systematic review and meta-analysis. *Pacing Clin Electrophysiol*. 2021  
473 Jun;44(6):1062–74.  
474

**Table 1. Baseline characteristics of participants**

<b>Variables</b>	<b>n=92</b>
Age (years) <sup>b</sup>	37 (27.5-50.5)
Male sex (n,%) <sup>c</sup>	45 (48.9)
Comorbidities (n,%) <sup>c</sup>	25 (27.2)
Smoking (n,%) <sup>c</sup>	32 (34.8)
Ivermectin (n,%) <sup>c</sup>	11 (12)
BMI (Kg/m <sup>2</sup> ) <sup>b</sup>	26.9 (24.4-30.1)
Weight status (n,%) <sup>c</sup>	
Normal weight	28 (30.4)
Overweight	41(44.6)
Obesity	23 (25)
Temperature (°C) <sup>b</sup>	36.6 (36.4-36.8)
Systolic pressure (mmHg) <sup>a</sup>	117.7 ± 13.7
Diastolic pressure (mmHg) <sup>a</sup>	78.6 ± 8.4
Corrected QT segment (ms) <sup>b</sup>	415.5 (394.2-432.7)
Oxygen saturation (%) <sup>b</sup>	94 (93-96)
NEWS (score) <sup>a</sup>	1 (0, 2)
Time of evolution until treatment start (days) <sup>b</sup>	5 (3, 6)
Elevated Gammaglutamyl transferase (n,%) <sup>c</sup>	42 (45.7)
Elevated DHL (n,%) <sup>c</sup>	25 (27.2)
Elevated de Glutamic Pyruvic Transaminase (n,%) <sup>c</sup>	24 (26.1)
<sup>c</sup>	
Elevated Glutamic Oxaloacetic Transaminase (n,%)	46 (50)

medRxiv preprint doi: <https://doi.org/10.1101/2022.04.06.22273531>; this version posted April 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

---

<sup>c</sup>

Anemia (n,%) <sup>c</sup>	45 (48.9)
Leukopenia (n,%) <sup>c</sup>	10 (10.9)
Leukocytosis (n,%) <sup>c</sup>	1 (1.1)
Neutropenia (n,%) <sup>c</sup>	8 (8.7)
Neutrophilia (n,%) <sup>c</sup>	3 (3.3)
Lymphopenia (n,%) <sup>c</sup>	27 (29.3)
Thrombocytopenia (n,%) <sup>c</sup>	20 (21.7)

---

medRxiv preprint doi: <https://doi.org/10.1101/2022.04.06.22271531>; this version posted April 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

<sup>a</sup> Data is presented as Mean and Standard Deviation, <sup>b</sup> data is presented as median and interquartile range 25-75 (IQR), <sup>c</sup> data is presented as frequencies and percentages.



**Table 2. General characteristics according to treatment arm**

Variables	Total n= 92	HCQ n=31	HCQ+AZT n=30	Placebo n=31	p
Age (years) <sup>b</sup>	37 (27.5-50.5)	38 (24-49.5)	41 (33.7-49.5)	32 (24-51)	0.34
Male sex (n,%) <sup>c</sup>	45 (48.9)	13 (41.9)	12 (40.0)	20 (64.5)	0.07
Comorbidities (n,%) <sup>c</sup>	25 (27.2)	9 (29.0)	7 (23.3)	9 (29.0)	1.0
Smoking (n,%) <sup>c</sup>	32 (34.8)	10 (32.3)	9 (30.0)	13 (41.9)	0.42
Time of evolution until treatment start (days) <sup>b</sup>	5 (3, 6)	5 (4, 6)	5 (3, 6)	5 (3, 7)	0.78
BMI (Kg/m <sup>2</sup> ) <sup>b</sup>	26.9 (24.4- 30.1)	26.9 (24.6-28.6)	27.3 (25.2-30.4)	25.6 (24.1-31.7)	0.53
Temperature (°C) <sup>b</sup>	36.6 (36.4-36.8)	36.7 (36.4-36.8)	36.6 (36.4-36.8)	36.6 (36.5- 36.8)	0.97
Systolic pressure (mmHg) <sup>a</sup>	117.7 ± 13.7	117.2 ± 13.9	117.0 ± 12.5	118.3 ± 14.7	0.93
Diastolic pressure (mmHg) <sup>a</sup>	78.6 ± 8.4	78.3 ± 8.1	78.5 ± 8.8	78.9 ± 8.8	0.97
Oxygen saturation (%) <sup>b</sup>	94 (93-96)	95 (93.7-96)	94 (92-95)	94 (93-96)	0.53
NEWS (score) <sup>b</sup>	1 (0,2)	0.5 (0, 2)	1 (0, 2)	2 (0, 2)	0.43
PCR (CT) <sup>a</sup>	26.6 ± 4.7	26.2 ± 4.8	26.4 ± 4.9	27.1 ± 4.5	0.72

Glucose (mg/dL) <sup>b</sup>	88.7 (79.3-96.3)	92.4 (75.5-101.6)	88.2 (78.8-99.5)	84.6 (79.6-92.5)	0.28
Urea (mg/dL) <sup>a</sup>	25.5 (21.1-33.1)	26.8 (21.0-33.6)	25.1 (19.5-33.3)	24.9 (22.1-32.8)	0.85
Lactic dehydrogenase (U/L) <sup>b</sup>	196.6 (164.6-221.1)	198.3 (158.4-231.4)	194.5 (167.7- 217.5)	182.9 (166.5-220.6)	0.97
Gamma Glutamyl Transferasa (U/L) <sup>b</sup>	32.9 (21.1-66.1)	31.8 (21.2-66.9)	35.8 (19.2- 73.3)	32.8 (21.9-65.7)	0.98
Glutamic Pyruvic Transaminase (U/L) <sup>b</sup>	33.6 (19.9- 55.3)	36.7 (21.6- 54.1)	33.4 (23.3- 58.7)	24.2 (15.4-54.3)	0.45
Glutamic Oxaloacetic Transaminase (U/L) <sup>b</sup>	31.5 (25.3- 44.5)	32.1 (27.7- 46.8)	32.0 (24.7- 42.1)	29.6 (23.7- 40.8)	0.53
Serum iron (ug/dL) <sup>a</sup>	50.8 (35.4-69.4)	48.5 (32.7- 69.8)	55.1 (37.6- 73.2)	47.2 (35.3-65.3)	0.56
Total leukocytes (K/ $\mu$ L) <sup>a</sup>	4.99 $\pm$ 1.49	5.1 $\pm$ 1.5	5.1 $\pm$ 1.6	4.8 $\pm$ 1.2	0.78
Neutrophils (K/ $\mu$ L) <sup>b</sup>	2.7 (2.3-3.8)	2.7 (2.3-4.1)	2.8 (2.1- 3.9)	2.7 (1.9-3.7)	0.71
Lymphocytes (K/ $\mu$ L) <sup>a</sup>	1.2 $\pm$ 0.4	1.2 $\pm$ 0.4	1.2 $\pm$ 0.4	1.2 $\pm$ 0.4	0.99
Platelets (K/ $\mu$ L) <sup>b</sup>	212 (172-256.5)	212 (175-257)	202 (157.7- 266)	218.5 (181-257.5)	0.76

<sup>a</sup> Data is presented as Mean, Standard Deviation and statistical was done was ANOVA, <sup>b</sup> data is presented as median and interquartile range 25-75 (IQR), statistical test was Kruskal Wallis, <sup>c</sup> data is presented as frequencies and percentages, statistical test was X<sup>2</sup>

**Table 3. Efficacy of treatment for primary and secondary outcomes**

Outcomes	HCQ+AZT n=30	HCQ n=31	Placebo n=31	HCQ+AZT vs Placebo RR (CI 95%)	NNH	p	HCQ vs Placebo RR (IC 95%)	NNH	p
<b>Primary</b>									
Hospitalization	2 (6.7%)	0 (0%)	0 (0%)	NC	-	-	NC	-	-
<b>Secondary outcomes</b>									
Progression	9 (30%)	13 (41.9%)	4 (12.9%)	2.32 (0.80, 6.74)	-	0.10	3.25 (1.19, 8.87)	-	0.01
Pneumonia	9 (30%)	10 (32.2%)	3 (9.6%)	3.1 (0.92, 10.3)	4.7	0.06	3.33 (1.01, 10.9)	4.4	0.02
Use of supplementary oxygen	6 (20%)	2 (6.4%)	1 (3.2%)	6.2 (0.79, 48.4)	-	0.10	2.0 (0.19, 20.9)	-	0.61

Negative test on day	21 (87.5%)	27 (90%)	30 (96.8%)	0.90 (0.76-1.06)	-	0.30	0.93 (0.81-1.06)	-	0.354
----------------------	------------	----------	------------	------------------	---	------	------------------	---	-------

11<sup>a</sup>

**a Data were missing for 7 patients in the group with HCQ+AZT**

**Figure 1. Efficacy of HCQ+AZT vs placebo for secondary outcomes**





Figure 2. Efficacy of HCQ vs placebo for secondary outcomes



j

Table 4. Efficacy of placebo vs active treatment for primary and secondary outcomes

Outcomes	Placebo n=31	Otros tratamientos n=61	RR	p	NNT	RAR
<b>Secondary</b>						
Progression	4 (12.9%)	22 (36.1%)	0.35 (0.13, 0.94)	0.02	4.3	23.2
Pneumonia	3 (9.6%)	19 (31%)	0.31 (0.09, 0.96)	0.02	4.6	21.4
Use of supplementary oxygen	1 (3.2%)	8 (13.1%)	0.24 (0.03, 1.87)	0.13	-	-

**Table 5. Adverse events according to treatment group**

Adverse event	Total	HCQ+AZT	HCQ	Placebo	<i>p</i>
	559	177	213	169	
Duration of the QTc segment (ms) at the end of the follow-up <sup>a</sup>	416 (390- 434)	413 (387-439)	421 (396-430)	413 (384-435)	0.903
Gastrointestinal, n (%)	93 (16.6)	33 (18.6)	36 (16.9)	24 (14.2)	0.269
Urticaria, n (%)	5 (0.9)	0 (0)	4 (1.9)	1 (0.6)	0.541
Dizziness, n (%)	14 (2.5)	3 (1.7)	5 (2.3)	6 (3.6)	0.271
Hypoglicemia, n (%)	12 (2.1)	3 (1.7)	4 (1.9)	5 (3.0)	0.421
Thrombocytosis, n (%)	24 (4.3)	6 (3.4)	9 (4.2)	9 (5.3)	0.376
Hypertriglyceridemia, n (%)	21 (3.8)	5 (2.8)	8 (3.8)	8 (4.7)	0.508
Bradycardia, n (%)	36 (6.4)	13 (7.3)	11 (5.2)	12 (7.1)	0.916
Others, n (%)	349 (62.4)	111 (62.4)	134 (62.9)	104 (61.5)	0.573

Median, interquartile range, Kruskal Wallis test

